Progenics Pharmaceuticals Inc. and Wyeth Pharmaceuticals Inc. have received FDA approval for their Relistor, a treatment for opioid-induced constipation. Relistor (methylnaltrexone bromide) is a subcutaneous injection for patients with advanced illness who receive palliative care and who have not responded to laxative therapy.